The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients. 2010

Yuya Yoshida, and Mitsutoshi Nakada, and Tomoya Harada, and Shingo Tanaka, and Takuya Furuta, and Yasuhiko Hayashi, and Daisuke Kita, and Naoyuki Uchiyama, and Yutaka Hayashi, and Jun-ichiro Hamada
Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.

Although there are many reports on the clinical use of the MIB-1 labeling index (LI), which is a measure of proliferative activity in astrocytomas; its significance varies between studies. There are no known molecules that are directly linked to the MIB-1 LI in astrocytomas. We evaluated the clinical value of the MIB-1 LI in our human glioblastoma cases and determined the molecules that possibly influenced the MIB-1 LI. An immunohistochemical study of the MIB-1 protein was performed and MIB-1 LIs of 38 glioblastomas were determined. In the same cases, epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor-alpha (PDGFRA), and sphingosine-1-phosphate receptor type 1 (S1P(1)), which are known regulators of glioma cell proliferation, were detected and quantified by quantitative real-time-PCR or western blotting. Kaplan-Meier survival curves for 38 patients with glioblastomas showed that a high MIB-1 LI correlated with poor survival (P < 0.05). Among the molecules tested, only the low expression of S1P(1) was significantly correlated with the high MIB-1 LI in glioblastomas (P < 0.05). Multivariate analysis revealed that the S1P(1) expression level was a significant prognostic factor. Our results indicate that the MIB-1 LI is an important prognostic factor in human glioblastomas. Furthermore, downregulation of S1P(1) expression increases proliferative activity, and thus enhances the malignancy of glioblastomas, resulting in a poor survival.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000081025 Sphingosine-1-Phosphate Receptors A subfamily of lysophospholipid receptors with specificity for sphingosine-1-phosphate (e.g., FINGOLIMOD), sphinganine 1-phosphate, 4-hydroxysphinganine 1-phosphate. Sphingosine-1-Phosphate Receptor 1,Sphingosine-1-Phosphate Receptor 2,Sphingosine-1-Phosphate Receptor 3,Sphingosine-1-Phosphate Receptor 4,Sphingosine-1-Phosphate Receptor 5,AGR16 Protein,EDG5 Protein,Edg Receptors,Edg-5 Receptor,G-Protein Coupled Receptor H218,H218 Protein,Nrg-1 Receptor,Receptor, Sphingosine-1-Phosphate,S1P Receptor,S1P1 Receptor,S1P2 Receptor,S1P3 Receptor,S1P4 Receptor,S1P5 Receptor,Sphingosine 1-Phosphate Receptor,Sphingosine-1-Phosphate Receptor,Edg 5 Receptor,G Protein Coupled Receptor H218,Nrg 1 Receptor,Sphingosine 1 Phosphate Receptor,Sphingosine 1 Phosphate Receptor 1,Sphingosine 1 Phosphate Receptor 2,Sphingosine 1 Phosphate Receptor 3,Sphingosine 1 Phosphate Receptor 4,Sphingosine 1 Phosphate Receptor 5,Sphingosine 1 Phosphate Receptors
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

Yuya Yoshida, and Mitsutoshi Nakada, and Tomoya Harada, and Shingo Tanaka, and Takuya Furuta, and Yasuhiko Hayashi, and Daisuke Kita, and Naoyuki Uchiyama, and Yutaka Hayashi, and Jun-ichiro Hamada
June 2023, Journal of neuro-oncology,
Yuya Yoshida, and Mitsutoshi Nakada, and Tomoya Harada, and Shingo Tanaka, and Takuya Furuta, and Yasuhiko Hayashi, and Daisuke Kita, and Naoyuki Uchiyama, and Yutaka Hayashi, and Jun-ichiro Hamada
January 2013, Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,
Yuya Yoshida, and Mitsutoshi Nakada, and Tomoya Harada, and Shingo Tanaka, and Takuya Furuta, and Yasuhiko Hayashi, and Daisuke Kita, and Naoyuki Uchiyama, and Yutaka Hayashi, and Jun-ichiro Hamada
October 1998, Journal of neuropathology and experimental neurology,
Yuya Yoshida, and Mitsutoshi Nakada, and Tomoya Harada, and Shingo Tanaka, and Takuya Furuta, and Yasuhiko Hayashi, and Daisuke Kita, and Naoyuki Uchiyama, and Yutaka Hayashi, and Jun-ichiro Hamada
January 2004, Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,
Yuya Yoshida, and Mitsutoshi Nakada, and Tomoya Harada, and Shingo Tanaka, and Takuya Furuta, and Yasuhiko Hayashi, and Daisuke Kita, and Naoyuki Uchiyama, and Yutaka Hayashi, and Jun-ichiro Hamada
January 2000, Journal of neuro-oncology,
Yuya Yoshida, and Mitsutoshi Nakada, and Tomoya Harada, and Shingo Tanaka, and Takuya Furuta, and Yasuhiko Hayashi, and Daisuke Kita, and Naoyuki Uchiyama, and Yutaka Hayashi, and Jun-ichiro Hamada
August 2012, The Journal of pharmacology and experimental therapeutics,
Yuya Yoshida, and Mitsutoshi Nakada, and Tomoya Harada, and Shingo Tanaka, and Takuya Furuta, and Yasuhiko Hayashi, and Daisuke Kita, and Naoyuki Uchiyama, and Yutaka Hayashi, and Jun-ichiro Hamada
August 1998, Nihon Jibiinkoka Gakkai kaiho,
Yuya Yoshida, and Mitsutoshi Nakada, and Tomoya Harada, and Shingo Tanaka, and Takuya Furuta, and Yasuhiko Hayashi, and Daisuke Kita, and Naoyuki Uchiyama, and Yutaka Hayashi, and Jun-ichiro Hamada
April 2010, Brain tumor pathology,
Yuya Yoshida, and Mitsutoshi Nakada, and Tomoya Harada, and Shingo Tanaka, and Takuya Furuta, and Yasuhiko Hayashi, and Daisuke Kita, and Naoyuki Uchiyama, and Yutaka Hayashi, and Jun-ichiro Hamada
February 2011, Neurology,
Yuya Yoshida, and Mitsutoshi Nakada, and Tomoya Harada, and Shingo Tanaka, and Takuya Furuta, and Yasuhiko Hayashi, and Daisuke Kita, and Naoyuki Uchiyama, and Yutaka Hayashi, and Jun-ichiro Hamada
October 1998, Journal of neuro-oncology,
Copied contents to your clipboard!